| Literature DB >> 32727156 |
Esra Cansever Mutlu1,2, Özge Kaya3, Matthew Wood4, Imre Mager4, Kübra Çelik Topkara5, Çağrı Çamsarı6, Arzu Birinci Yildirim7, Ayhan Çetinkaya5, Diğdem Acarel8, Jale Odabaşı Bağcı9.
Abstract
Immature dendritic cells (IDc), 'dexosomes', are promising natural nanomaterials for cancer diagnose and therapy. Dexosomes were isolated purely from small-scale-up production by using t25-cell-culture flasks. Total RNA was measured as 1.43 ± 0.33 ng/106 cell. Despite the fact that they possessed a surface that is highly abundant in protein, this did not become a significant effect on the DOX loading amount. Ultrasonication was used for doxorubicin (DOX) loading into the IDc dexosomes. In accordance with the literature, three candidate DOX formulations were designed as IC50 values; dExoIII, 1.8 µg/mL, dExoII, 1.2 µg/mL, and dExoI, 0.6 µg/mL, respectively. Formulations were evaluated by MTT test against highly metastatic A549 (CCL-185; ATTC) cell line. Confocal images of unloaded (naïve) were obtained by CellMaskTM membrane staining before DOX loading. Although, dexosome membranes were highly durable subsequent to ultrasonication, it was observed that dexosomes could not be stable above 70 °C during the SEM-image analyses. dExoIII displayed sustained release profile. It was found that dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA) results were in good agreement with each other. Zeta potentials of loaded dexosomes have approximately between -15 to -20 mV; and, their sizes are 150 nm even after ultrasonication. IDcJAWSII dexosomes can be able to be utilized as the "BioNanoMaterial" after DOX loading via ultrasonication technique.Entities:
Keywords: A549 Cells; JAWSII; doxorubicin; exosome; natural nanoparticles; ultrasonication
Year: 2020 PMID: 32727156 PMCID: PMC7435586 DOI: 10.3390/ma13153344
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.623
Figure 1Confocal images at 488 nm with several magnifications as defined while (a) high and (b) low magnification of naïve dexosomes 2 h following staining (c) only CellMask Green dye (d) blank as the control.
Figure 2NTA results of dexosomes (a) naive: 99 nm; (b) dExOI: 134 nm; (c) dExOII: 142 nm; (d) dExOIII: 148 nm.
Figure 3DLS results of (a) dexOI are 133 nm and (b) −20 mV; (c) dExOIIII are 161 nm and (d) −15 mV.
Comparative NTA, Z-intensity, and surface charge results of naïve and dExO dexosomes.
| Sample/Method | Size by NTA (nm) | Z-Intensity (nm) | Zeta Potential (mv) |
|---|---|---|---|
| Naïve | 99.2 ± 2.7 | 209.4 ± 81.7 | −10.7 ± 7.39 |
| dExOIII | 148 ± 2.9 | 161.2 ± 19.26 | −15.9 ± 5.91 |
| dExOII | 142 ± 1.7 | 162.5 ± 17.14 | −18.8 ± 6.67 |
| dExOI | 134 ± 4.7 | 133.2 ± 9.6 | −20.2 ± 4.48 |
Figure 4Changes in size and zeta potential of dexosomes based on the amount of DOX in dExO.
Figure 5SEM images of dexosomes (a) naive; (b) dExOI; (c) dExOII; (d) dExOIII, respectively.
Figure 6Cytotoxicity of dExO formulations and DOX dosages against to A549 cancer cell line.
Figure 7Survival rate of control groups; naïve dexosomes, PBS, water, and DMSO against A549 cancer cell line.
Figure 8Drug release profile of dExOIII during 72 h.